Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Dravet Syndrome - Pipeline Review, H2 2016, provides an overview of the Dravet Syndrome (Central Nervous System) pipeline landscape.
Dravet syndrome, also known as severe myoclonic epilepsy of infancy (SMEI), is a rare and catastrophic form of intractable epilepsy that begins in infancy. Symptoms include ataxia (unsteadiness), sleep disturbance, and behavior problem.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Dravet Syndrome - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Dravet Syndrome (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Dravet Syndrome (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 2, 2, 2 and 1 respectively.Dravet Syndrome.
Dravet Syndrome (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Dravet Syndrome (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Dravet Syndrome (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Dravet Syndrome (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Dravet Syndrome (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Dravet Syndrome (Central Nervous System)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Dravet Syndrome (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Dravet Syndrome (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Companies Mentioned
Biscayne Pharmaceuticals Inc
GW Pharmaceuticals Plc
INSYS Therapeutics Inc
OPKO Health Inc
PTC Therapeutics Inc
Sage Therapeutics Inc
Xenon Pharmaceuticals Inc
Zogenix Inc
'
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Overview 7
Therapeutics Development 8
Pipeline Products for Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Overview 8
Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Therapeutics under Development by Companies 9
Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Early Stage Products 12
Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Products under Development by Companies 13
Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Companies Involved in Therapeutics Development 14
Biscayne Pharmaceuticals Inc 14
GW Pharmaceuticals Plc 15
INSYS Therapeutics Inc 16
OPKO Health Inc 17
PTC Therapeutics Inc 18
Sage Therapeutics Inc 19
Xenon Pharmaceuticals Inc 20
Zogenix Inc 21
Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Target 23
Assessment by Mechanism of Action 25
Assessment by Route of Administration 27
Assessment by Molecule Type 29
Drug Profiles 31
Antisense Oligonucleotide for Dravet Syndrome - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
ataluren - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
BIS-001 - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
cannabidiol - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
cannabidiol - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
CUR-1916 - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
fenfluramine hydrochloride - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
SAGE-217 - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
Small Molecule to Block Nav1.6 for Dravet Syndrome - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Dormant Projects 58
Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Product Development Milestones 59
Featured News & Press Releases 59
Nov 22, 2016: New Data on Zogenixs ZX008 for Lennox Gastaut Syndrome & Dravet Syndrome to be Presented at 70th Annual American Epilepsy Society Meeting 59
Oct 24, 2016: Newly Published Data Show Biscayne Pharmaceuticals' Novel Antiepileptic Drug Can Eliminate Seizures In Models Of Dravet Syndrome 60
Jun 28, 2016: Biscayne Pharmaceuticals Presents Data On Novel Antiepileptic Agent BIS-001 AT EILAT Conference On New Antiepileptic Drugs 61
Jun 27, 2016: GW Pharmaceuticals Announces Positive Phase 3 Pivotal Trial Results for Epidiolex (cannabidiol) in the Treatment of Lennox-Gastaut Syndrome 62
Jun 08, 2016: Xenon Pharmaceuticals Presents Update on Nav1.6 Sodium Channel Inhibitor at the Jefferies 2016 Healthcare Conference 64
Jun 07, 2016: Zogenix Announces Initiation of Multi-National Phase 3 Clinical Trial for ZX008 in Dravet Syndrome 64
May 05, 2016: Zogenix Announces ZX008 New Efficacy and Safety Data for Treatment of Seizures in Dravet Syndrome 65
Apr 21, 2016: New Data on Zogenix ZX008 for Dravet Syndrome to be Presented at 14th International Child Neurology Congress 66
Mar 14, 2016: GW Pharmaceuticals Announces Positive Phase 3 Pivotal Study Results for Epidiolex (cannabidiol) 66
Feb 25, 2016: Edison Issues ADR Update on GW Pharmaceuticals 68
Jan 19, 2016: Zogenix Receives Fast Track Designation From FDA for Development of ZX008 in Dravet Syndrome 68
Jan 11, 2016: Zogenix Announces Initiation of Phase 3 Program for ZX008 in Dravet Syndrome 69
Dec 14, 2015: Zogenix Announces FDA Acceptance of Investigational New Drug Application for ZX008 Phase 3 Clinical Trial in Dravet Syndrome 69
Dec 07, 2015: Biscayne Pharmaceuticals Presents Data At 2015 AES Meeting Confirming BIS-001 Is A Novel Mechanism, Highly Potent And Well-Tolerated Anti-Epileptic Drug 70
Dec 07, 2015: GW Pharmaceuticals Announces New Physician Reports of Epidiolex Treatment Effect in Children and Young Adults With Treatment-Resistant Epilepsy 70
Appendix 74
Methodology 74
Coverage 74
Secondary Research 74
Primary Research 74
Expert Panel Validation 74
Contact Us 74
Disclaimer 75
List of Tables
Number of Products under Development for Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy), H2 2016 8
Number of Products under Development by Companies, H2 2016 9
Comparative Analysis by Late Stage Development, H2 2016 10
Comparative Analysis by Clinical Stage Development, H2 2016 11
Comparative Analysis by Early Stage Development, H2 2016 12
Products under Development by Companies, H2 2016 13
Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Pipeline by Biscayne Pharmaceuticals Inc, H2 2016 14
Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Pipeline by GW Pharmaceuticals Plc, H2 2016 15
Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Pipeline by INSYS Therapeutics Inc, H2 2016 16
Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Pipeline by OPKO Health Inc, H2 2016 17
Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Pipeline by PTC Therapeutics Inc, H2 2016 18
Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Pipeline by Sage Therapeutics Inc, H2 2016 19
Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Pipeline by Xenon Pharmaceuticals Inc, H2 2016 20
Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Pipeline by Zogenix Inc, H2 2016 21
Assessment by Monotherapy Products, H2 2016 22
Number of Products by Stage and Target, H2 2016 24
Number of Products by Stage and Mechanism of Action, H2 2016 26
Number of Products by Stage and Route of Administration, H2 2016 28
Number of Products by Stage and Molecule Type, H2 2016 30
Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Dormant Projects, H2 2016 58
List of Figures
Number of Products under Development for Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy), H2 2016 8
Number of Products under Development by Companies, H2 2016 9
Comparative Analysis by Clinical Stage Development, H2 2016 11
Comparative Analysis by Early Stage Products, H2 2016 12
Assessment by Monotherapy Products, H2 2016 22
Number of Products by Targets, H2 2016 23
Number of Products by Stage and Targets, H2 2016 23
Number of Products by Mechanism of Actions, H2 2016 25
Number of Products by Stage and Mechanism of Actions, H2 2016 25
Number of Products by Routes of Administration, H2 2016 27
Number of Products by Stage and Routes of Administration, H2 2016 27
Number of Products by Molecule Types, H2 2016 29
Number of Products by Stage and Molecule Types, H2 2016 29
